inhibition mir-33a/b non-human primates raises plasma hdl lowers vldl triglycerides
cardiovascular disease remains leading cause mortality westernized countries despite optimum medical therapy reduce levels low-density lipoprotein ldl-associated cholesterol pursuit novel therapies target residual risk focused raising levels high-density lipoprotein hdl-associated cholesterol order exploit atheroprotective effects micrornas mirnas emerged important posttranscriptional regulators lipid metabolism thus new class target therapeutic intervention microrna-33a microrna-33b mir-33a/b intronic mirnas whose encoding regions embedded sterol-response-element-binding protein genes srebf2 srebf1 refs respectively mirnas repress expression cholesterol transporter abca1 key regulator hdl biogenesis recent studies mice suggest antagonizing mir-33a may effective strategy raising plasma hdl levels- providing protection atherosclerosis however extrapolating findings humans complicated fact mice lack mir-33b present srebf1 gene medium large mammals show african green monkeys systemic delivery anti-mirna oligonucleotide targets mir-33a mir-33b increased hepatic expression abca1 induced sustained increase plasma hdl levels weeks notably mir antagonism non-human primate model also increased expression mir target genes involved fatty acid oxidation crot cpt1a hadhb prkaa1 reduced expression genes involved fatty acid synthesis srebf1 fasn acly acaca resulting marked suppression plasma levels very-low-density lipoprotein vldl-associated triglycerides finding previously observed mice data establish model highly relevant humans pharmacological inhibition mir-33a mir33b promising therapeutic strategy raise plasma hdl lower vldl triglyceride levels treatment dyslipidaemias increase cardiovascular disease risk
